3.3. late-onset hypogonadism. testosterone production declines ageing. european male aging study (emas) reported 0.4% per annum (log hormone-age) decrease total testosterone 1.3% per annum decline free testosterone (ft) . late onset hypogonadism term frequently used describe phenomenon detection hypogonadism adulthood. evidence indicates several associated diseases chronic comorbidities interfere hpg axis leading development primary hypogonadism or, frequently, secondary hypogonadism adulthood, thus significantly influencing physiological age-dependent decline testosterone. combining data three different waves massachusetts male aging study (mmas), demonstrated associated comorbidity obesity significantly decreased, whereas smoking tended increase total, free bio-available testosterone concentrations . data derived emas confirmed findings . based upon data evidence, previously reported concept functional organic hypogonadism recently introduced (see above) . considering suppression hpg axis activity functional, potentially reversible empiric measures, weight loss, need testosterone therapy questioned . 3.3.1. clinical diagnosis evaluation mainstay loh diagnosis includes signs symptoms consistent hypogonadism, coupled biochemical evidence low morning serum total testosterone levels two occasions, measured reliable assay fasting conditions. 3.3.2. history taking specific symptoms associated hypogonadism, including loh, shown table 3. symptoms non-specific need recorded taken context clinical biochemical state. several self-reported questionnaires structural interviews developed screening hypogonadism. although case-history tools demonstrated clinical utility supporting biochemical diagnosis hypogonadism, assessment testosterone therapy outcomes, specificity remains poor used systematic screening hypogonadal men . headache and/or visual disturbance may indicate pituitary-related disorder. history surgical intervention cryptorchidism hypospadias must taken account possible signs congenital defects. chronic systemic comorbidities must comprehensively investigated every patient. use drugs potentially interfere hpg axis excluded (table 1). acute diseases associated development functional hypogonadism determination serum total testosterone levels avoided conditions; however, role testosterone case acute illness remains clarified . fertility issues always discussed. table 3: specific symptoms associated loh sexual symptomsphysical symptomspsychological symptomsmore specificreduced libidoerectile dysfunctiondecreased spontaneous/morning erectionsdecreased vigorous activitydifficulty walking > 1 kmdecreased bendinglow mood/mood deflectiondecreased motivationfatigueless specificreduced frequency sexual intercoursereduced frequency masturbationdelayed ejaculationhot flushesdecreased energydecreased physical strength/function/ activityconcentration difficultiessleep disturbances 3.3.3. physical examination since obesity frequently associated hypogonadism (mostly functional), determination body mass index (bmi) measurement waist circumference strongly recommended individuals. testicular penile size, well presence sexual secondary characteristics provide useful information regarding overall androgen status. addition, upper segment/lower segment ratio (n.v. > 0.92) arm-span height ratio (n.v. < 1.0) useful identify eunuchoid body shape, especially subjects pre-pubertal hypogonadism delayed puberty. finally, digital rectal examination (dre) performed subjects exclude prostate abnormalities testosterone therapy (any type) support suspicion hypogonadism (in case reduced volume) . 3.3.4. laboratory diagnostics testosterone levels produced circadian variation, may persist ageing men . testosterone levels also potentially influenced food intake ; therefore, serum total testosterone measured fasting conditions morning (between 07.00 11.00 hours). confirmatory measurement always undertaken case primary pathological value, starting testosterone therapy. liquid chromatography-tandem mass spectrometry (lc-ms/ms) represents accurate method sex steroid evaluation; however, standardised automated platform immuno-assays total testosterone assessment demonstrate good correlation lc-ms/ms . available immuno-assays able provide accurate estimation ft; therefore, direct ft evaluation methods recommended avoided . equilibrium dialysis accurate method total testosterone measurement ft calculation . alternatively, ft derived specific mathematical calculations using total testosterone derived common immunoassays taking account serum sex hormone binding globulin (shbg) albumin levels (http://www.issam.ch/freetesto.htm). data meta-analyses shown testosterone therapy ineffective baseline levels > 12 nmol/l (3.5 ng/ml). positive outcomes documented testosterone levels < 12 nmol/l, higher symptomatic patients severe forms hypogonadism (< 8 nmol/l). hence, 12 nmol/l considered possible threshold starting testosterone therapy presence hypogonadal symptoms . clinical conditions may interfere shbg levels, evaluation ft considered better estimate actual androgen levels (figure 1). unfortunately, despite potential clinical value , validated thresholds ft available clinical studies represents area uncertainty; however, data emas indicated ft levels < 220 pmol/l (6.4 ng/dl) increased likelihood correct identify hypogonadism compared total testosterone level alone, particularly total testosterone levels 8.0 11 nmol per litre . determination lh must performed along prolactin (prl) pathological total testosterone levels detected, order correctly define underlying conditions exclude possible organic causes (figure 1). follicle-stimulating hormone determination support diagnosis primary secondary hypogonadism . due negative influence libido, prl also considered first-line screening patients reduced sexual desire. addition, contrast-enhanced pituitary magnetic resonance imaging (mri) scanning, well pituitary hormone evaluations, required presence specific symptoms visual disturbances, headache hyperprolactinemia confirmed . limited evidence suggests also performing pituitary mri case severe hypogonadism (< 6 nmol/l, 1.75 ng/ml) inadequate gonadotropin levels (figure 1) [74-76]. 3.3.5. summary evidence recommendations diagnostic evaluation screening loh summary evidencelesexual symptoms specific symptoms associated late-onset hypogonadism (loh).1adiagnosis loh based specific signs symptoms androgen deficiency, together consistently low serum testosterone levels.1atotal testosterone 12 nmol/l (3.5 ng/ml) represents reliable threshold diagnose loh.1afunctional hypogonadism consequence comorbidity/concomitant drugs, impair testosterone production adulthood. diagnosis functional hypogonadism diagnosis exclusion, ruling organic causes hypogonadism.4calculated free-testosterone < 220 pmol/l suggested possible cut-off diagnose loh.3self-reported questionnaires structural interviews developed screening hypogonadism specificity remains poor.2a recommendationsstrength ratingdiagnostic evaluationcheck concomitant diseases, drugs substances interfere testosterone production/action.strongmeasure total testosterone morning (between 07.00 11.00 hours) fasting state, reliable laboratory assay.strongrepeat total testosterone least two separate occasions < 12 nmol/l starting testosterone therapy.stronguse 12 nmol/l total testosterone (3.5 ng/ml) reliable threshold diagnose late onset hypogonadism (loh).strongmeasure sex hormone-binding globulin free-testosterone calculation indicatedstronganalyse luteinising hormone follicle-stimulating hormone serum levels differentiate different types hypogonadism.strongmeasure prolactin (prl) levels evidence low sexual desire (or suggestive signs/symptoms) secondary hypogonadism present.strongperform pituitary magnetic resonance imaging (mri) secondary hypogonadism, elevated prl symptoms specific pituitary mass and/or presence anterior pituitary hormone deficiency.strongperform pituitary mri secondary severe hypogonadism (total testosterone < 6 nmol/l).weakscreeningscreen late onset hypogonadism (loh) symptomatic men.strongdo use structured interviews self-reported questionnaires systematic screening loh low specificity.strong figure 1: diagnostic evaluation late-onset hypogonadism tt = total testosterone; cft = calculated free testosterone; prl = prolactin; shbg = sex hormone-binding globulin; lh = luteinising hormone; mri = magnetic resonance imaging.